Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) to Post Q4 2025 Earnings of $0.65 Per Share, Zacks Research Forecasts

Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) – Research analysts at Zacks Research decreased their Q4 2025 earnings estimates for shares of Catalyst Pharmaceuticals in a research note issued on Wednesday, April 24th. Zacks Research analyst A. Chakraborty now forecasts that the biopharmaceutical company will post earnings per share of $0.65 for the quarter, down from their prior forecast of $0.66. The consensus estimate for Catalyst Pharmaceuticals’ current full-year earnings is $1.81 per share. Zacks Research also issued estimates for Catalyst Pharmaceuticals’ Q1 2026 earnings at $0.76 EPS and FY2026 earnings at $3.45 EPS.

A number of other equities analysts have also recently commented on the stock. HC Wainwright reiterated a “buy” rating and issued a $24.00 target price on shares of Catalyst Pharmaceuticals in a research report on Friday, March 1st. TheStreet upgraded Catalyst Pharmaceuticals from a “c+” rating to a “b” rating in a report on Tuesday, March 12th. Bank of America assumed coverage on Catalyst Pharmaceuticals in a report on Thursday, March 7th. They issued a “buy” rating and a $23.00 price objective for the company. StockNews.com upgraded Catalyst Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Thursday, March 21st. Finally, Cantor Fitzgerald reiterated an “overweight” rating and issued a $34.00 price objective on shares of Catalyst Pharmaceuticals in a report on Friday, March 22nd. Six equities research analysts have rated the stock with a buy rating, According to data from MarketBeat, Catalyst Pharmaceuticals has a consensus rating of “Buy” and an average target price of $26.43.

Catalyst Pharmaceuticals Stock Up 1.4 %

Shares of NASDAQ:CPRX opened at $14.89 on Thursday. The stock has a market cap of $1.76 billion, a PE ratio of 24.07, a PEG ratio of 0.83 and a beta of 0.89. The company’s fifty day moving average is $15.52 and its 200 day moving average is $14.61. Catalyst Pharmaceuticals has a 52 week low of $11.09 and a 52 week high of $17.76.

Catalyst Pharmaceuticals (NASDAQ:CPRX) last issued its earnings results on Wednesday, February 28th. The biopharmaceutical company reported $0.49 EPS for the quarter, topping analysts’ consensus estimates of $0.45 by $0.04. The company had revenue of $110.57 million for the quarter, compared to analysts’ expectations of $105.78 million. Catalyst Pharmaceuticals had a net margin of 17.93% and a return on equity of 26.56%.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the company. Parkside Financial Bank & Trust bought a new position in Catalyst Pharmaceuticals during the 4th quarter valued at approximately $31,000. GAMMA Investing LLC increased its position in Catalyst Pharmaceuticals by 72.9% during the 1st quarter. GAMMA Investing LLC now owns 1,942 shares of the biopharmaceutical company’s stock valued at $31,000 after buying an additional 819 shares in the last quarter. Nisa Investment Advisors LLC increased its position in Catalyst Pharmaceuticals by 306.3% during the 4th quarter. Nisa Investment Advisors LLC now owns 5,079 shares of the biopharmaceutical company’s stock valued at $85,000 after buying an additional 3,829 shares in the last quarter. Tower Research Capital LLC TRC increased its position in Catalyst Pharmaceuticals by 84.5% during the 4th quarter. Tower Research Capital LLC TRC now owns 6,184 shares of the biopharmaceutical company’s stock valued at $104,000 after buying an additional 2,833 shares in the last quarter. Finally, Sherbrooke Park Advisers LLC bought a new position in Catalyst Pharmaceuticals during the 3rd quarter valued at approximately $123,000. Institutional investors own 79.22% of the company’s stock.

Insider Transactions at Catalyst Pharmaceuticals

In other news, Director David S. Tierney sold 25,000 shares of the stock in a transaction that occurred on Monday, April 8th. The stock was sold at an average price of $15.68, for a total value of $392,000.00. Following the completion of the transaction, the director now owns 348,874 shares of the company’s stock, valued at approximately $5,470,344.32. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Corporate insiders own 12.10% of the company’s stock.

Catalyst Pharmaceuticals Company Profile

Catalyst Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients.